RBC Capital Initiates Coverage On Corbus Pharmaceuticals with Outperform Rating, Announces Price Target of $77
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has initiated coverage on Corbus Pharmaceuticals (CRBP) with an Outperform rating and set a price target of $77.
May 13, 2024 | 11:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital initiated coverage on Corbus Pharmaceuticals with an Outperform rating and a price target of $77, indicating a positive outlook on the stock.
The initiation of coverage by RBC Capital with an Outperform rating and a high price target suggests a strong positive sentiment towards Corbus Pharmaceuticals. This is likely to attract investor attention and could lead to a short-term increase in stock price, given the credibility of RBC Capital's analysis.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100